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Implication for health policy/practice/research/medical education:
Prevention is always better than a cure. Following a healthy lifestyle can protect us against many diseases; it is demonstrated in 
the slogan of  the World Kidney Day suggesting a healthy lifestyle for a healthy kidney.
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Context: Numerous studies have reported the impact of obesity in the incidence of 
chronic kidney disease (CKD). Some studies have suggested the direct role of obesity in 
the incidence of CKD, while some other studies suggest an indirect effect caused by the 
effects of obesity on blood pressure and diabetes. 
Evidence Acquisition: PubMed, EBSCO, Web of Science, directory of open access journals 
(DOAJ), EMBASE, and Google Scholar have been searched.
Results: Recent studies have presented more strong evidences on the role of obesity on 
the incidence of CKD. The double role of obesity in the incidence of CKD has also been 
mentioned in some studies. 
Conclusions: Such an additional effect arises from the impact of obesity on the incidence of 
some conditions and diseases such as cardiovascular disease, hypertension, and diabetes, 
which in turn are involved in the incidence of CKD and are considered as its risk factors.
ABSTRACT
1. Context
Obesity is one of  the problems facing the healthcare 
system in the world. According to the reports by the 
World Health Organization (WHO), in 2008 around 
1.4 billion were overweight and 500 million were 
obese (1). Two-thirds of  adults in the United States 
are overweight and about one-third of  them are obese 
(2).
Obesity is a complex problem which can play a role 
in the incidence of  many metabolic problems such as 
diabetes, dyslipidemia, hypertension, and metabolic 
syndrome. Recently, various studies have reported its 
role in chronic kidney disease (CKD) as well (3, 4). 
Some studies suggest that obesity may increase the 
risk of  developing CKD by as much as two to three 
times (3).
Obesity is associated with increased glomerular 
filtration, increased risk of  cardiovascular diseases 
and microalbuminuria (5-10). Some studies have 
suggested that kidney dysfunction in obese people 
is an independent risk factor for developing CKD 
(11,12).
A study suggests that the incidence of  abdominal 
obesity in young people is an independent risk factor 
for the incidence of  CKD and is associated with the 
race. Therefore, obese young people are recommended 
to conduct kidney function tests on a regular basis 
(13).
Given the importance of  CKD, the increasing 
incidence of  obesity, differences in the living 
conditions of  people in different communities (14,15), 
and the likely relationship between obesity and CKD, 
this study aimed to review the previously published 
papers to evaluate the relationship between these 
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two (obesity and CKD) and determine the related 
prevention methods.
2. Evidence Acquisition
PubMed, EBSCO, directory of  Open Access Journals 
(DOAJ), Google Scholar, and Web of  Science were 
searched with key words as chronic kidney disease, 
end-stage renal disease and obesity. We searched and 
reviewed the papers published in scientific journals 
during a 10-year period (from 2007 to 2016). 
3. CKD and its risk factors
CKD is a health problem that can progress and lead 
to end-stage renal disease (ESRD). It can increase 
mortality from heart diseases. Available statistics 
indicate that 10% to 16% of  adults in different parts 
of  the world are affected by CKD (16).
Several underlying items and risk factors for 
developing CKD have been proposed, among which 
we may note the followings: genetic factors, age, 
sex, race, culture, family history, drug use, smoking, 
socioeconomic status, and concomitant disorders 
such as hypertension and diabetes.
Some studies have suggested the influence of  genetic 
factors and environmental factors in the development 
of  CKD (17). Such studies have noted the relationship 
between the gene associated with glomerular filtration 
rate and the disease, they suggest that mutations in 
this gene can be associated with changes in renal 
function (18). Apolipoprotein L1 (APOL1) gene is 
the other gene associated with CKD; it increases the 
risk of  nephropathy induced by immunodeficiency 
syndrome, focal glomerulosclerosis, CKD associated 
with hypertension, and CKD unrelated to diabetes 
especially in the black population (17). In addition, the 
gene associated with the renin angiotensin system also 
plays a role in the incidence of  CKD (19).
In 23% of  dialysis patients, there is a family history 
of  ESRD. The previously conducted studies have 
recommended performing kidney disease tests and 
examinations for all the family members of  dialysis 
patients (20).
In previous studies, ESRD was more prevalent in 
males. In other words, it has been 1.41 time more 
prevalent among males than among females (21).
People’s race is the other important risk factors for 
ESRD. It is well-documented that African-Americans 
have a higher prevalence of  ESRD than Americans 
European people. The risk of  the incidence of  ESRD 
in black women was higher than that in black men. On 
contrary, the risk of  incidence of  ESRD was lower in 
white women, as compared with the white men (22).
Age was also a factor influencing the incidence of 
CKD. In people over 30 years of  age, with increasing 
every 10 years of  age, the risk of  CKD increases by 
1.45 to 2.18 times (23). Socioeconomic status also 
plays a role in the incidence of  CKD. According to 
previously conducted studies, the risk of  developing 
CKD in people with low socioeconomic status 
increased by up to 2.4 times (24).
Smoking also plays a role in the incidence of  CKD. 
Smoking is associated with increased incidence of 
pro-inflammatory state, oxidative stress, endothelial 
dysfunction, glomerulosclerosis, and tubular atrophy 
and can play a role in the increased risk of  CKD (25).
Among the other known causes of  chronic renal failure, 
we may note the followings entities as nephrotoxic 
drugs (26), acute renal damage (27), diabetes mellitus 
(22), hypertension (28), obstructive sleep apnea (OSA) 
(25), elevated heart rate (29), periodontal diseases (30), 
and finally obesity (31).
Obesity is one of  the most important risk factors 
for the incidence of  CKD which is preventable (31). 
Glomerular hypertrophy and increased filtration can 
accelerate kidney damage through increasing the 
pressure of  glomerular capillary wall and reducing the 
density of  cells in the Bowman’s capsule (31).
Previously conducted studies have investigated the 
role of  obesity in the incidence of  CKD. In a study 
which was conducted in Sweden, people aged 18 to 
74 years old with a creatinine level of  3.4 in males and 
2.8 in females were investigated. The results of  the 
mentioned study showed that the risk of  developing 
CKD in people aged over 20 years with a body mass 
index (BMI) higher than 25 was up to 3 times more 
than the risk in those with a BMI less than 25. Obesity 
in men (BMI more than 30) and excessive obesity in 
women (BMI more than 35) can increase the risk of 
CKD by three to four times (25).
Obesity is an epidemic in the 21st century. Obesity 
is one of  the risk factors for diabetes type II, cancer, 
hypertension, dyslipidemia, cardiovascular diseases, 
sleep apnea, and CKD. Obesity increases the risk 
of  hypertension, atherosclerosis, and diabetes type 
II, which in turn increase the risk of  developing 
CKD (32).
Obesity and overweight, with or without metabolic 
syndrome, are associated with an increased risk of 
CKD. Studies have shown that overweight and obesity, 
even in the absence of  metabolic syndrome, are not 
benign factors and can result in developing CKD. 
Obesity and overweight are the risk factors for CKD, 
however, this relationship is not very strong. Overall, 
the previously conducted studies recommended 
conducting more studies to prove the relationship (33).
Obesity also has a direct effect on the incidence of 
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CKD. According to the results of  a study, a 12% 
body weight loss in patients with advanced diabetic 
nephropathy in the short term improved the glomerular 
filtration and kidney function indicators and reduced 
the risk factors for kidney disease progression (34).
Early diagnosis of  CKD risk factors makes it possible 
to eliminate them and prevent the progress of  the 
disease. Obesity is one of  the preventable risk factors. 
According to a study, the risk of  CKD in the obese 
patients is 1.71 times more than that in the general 
population (odds ratio: 1.71, 95% CI: 1.14-2.59). The 
mentioned study noted that many CKD risk factors 
including obesity can be detected and corrected 
before CKD diagnosis, therefore early detection and 
correction of  these factors is of  great importance (35).
In another study it was observed that obese individuals 
with CKD differed from obese people without CKD 
in terms of  behavioral factors, lifestyle, and attitudes 
toward obesity. It was also found that the studied 
people had inadequate knowledge on the role of 
obesity in the incidence of  CKD. However, the study 
suggests conducting further studies to prove the role 
of  obesity in the incidence of  CKD (36).
Other forms of  obesity, such as abdominal obesity, are 
among the risk factors for CKD. Abdominal obesity 
can be an independent risk factor for the development 
of  albuminuria, even in people with normal blood 
pressure and normal glucose level (13). Accordingly, it 
highlights the value of  adopting measures to prevent 
abdominal obesity, especially in young people.
Obesity is known as one of  the risk factors for CKD, 
but its role has not clearly been determined yet. 
Previous studies have suggested the role of  changes 
in the secretion of  adipokine, however further studies 
are needed to prove its role (37).
Numerous other studies have reported the impact of 
obesity in the incidence of  CKD. Some studies have 
suggested the direct role of  obesity in the incidence 
of  CKD while some other studies suggest an indirect 
effect caused by the effects of  obesity on blood 
pressure and diabetes (38-40). However, more recent 
studies have presented more strong evidences on the 
role of  obesity on the incidence of  CKD (41,42).
The double role of  obesity in the incidence of  CKD 
has also been mentioned in some studies. Such an 
additional effect arises from the impact of  obesity on 
the incidence of  some conditions and diseases such 
as cardiovascular disease, hypertension, and diabetes, 
which in turn are involved in the incidence of  CKD 
and are considered as its risk factors (43,44).
4. Conclusions
Many people around the world are suffering 
from CKD. Sometimes the disease is latent and 
asymptomatic, thus the patient is not aware of  its own 
condition. In such a condition, the patient becomes 
aware of  the disease when it has progressed much and 
even reached an irreversible point. Early diagnosis of 
the disease and the identification of  its risk factors 
and correcting them is of  great value.
Obesity (including abdominal obesity) is one of  the 
risk factors for CKD. Obesity is associated with other 
chronic diseases such as cardiovascular diseases, 
diabetes, and hypertension which are among the 
predisposing factors for the development of  CKD.
Obesity is a modifiable risk factor and it can be 
prevented through the utilization of  a healthy diet, 
exercise, and physical activity.
Given the importance of  early diagnosis of  CKD 
and its role in the prevention of  irreversible kidney 
damages, it is better to consider renal function tests as 
part of  routine examinations for all high-risk groups 
including those who are obese or overweight. It can 
help to modify the risk factors in a timely manner and 
prevent the progress of  the disease and the subsequent 
irreversible complications.
Prevention is always better than a cure. Following a 
healthy lifestyle can protect us against many diseases; 
it is demonstrated in the slogan of  the World Kidney 
Day suggesting a healthy lifestyle for a healthy kidney.
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